Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Persistent Pulmonary Hypertension, Respiratory Failure
Interventions: Intravenous Sildenafil, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Hours
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more

Conditions: COVID-19
Interventions: Brilacidin, Placebo, Standard of Care (SoC); Drug
Lead sponsor: Innovation Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Winfield, Illinois • Toledo, Ohio

Conditions: Migraine
Interventions: LY3451838, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more

Conditions: Phenylketonurias
Interventions: sapropterin dihydrochloride; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 8 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: Los Angeles, California • Oakland, California • New Haven, Connecticut + 10 more

Conditions: Acute Pain, Postoperative Pain Control
Interventions: Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose, Active Comparator: HB/APAP, Placebo Comparator; Drug
Lead sponsor: Latigo Biotherapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Atlanta, Georgia • Houston, Texas + 2 more

Conditions: Prostate Cancer
Interventions: Enoblituzumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
Interventions: Binimetinib, Encorafenib, Nivolumab; Drug · Biological
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atopic Dermatitis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Tumor Necrosis Factor; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
Interventions: Radiotherapy combined with cisplatin, Cisplatin; Radiation · Drug
Lead sponsor: University Medical Center Groningen; Other
Eligibility: 18 Years and older · Female only
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 21
States / cities: Orange, California • Miami Beach, Florida • Springfield, Massachusetts + 18 more

Conditions: Sarcoma
Interventions: sorafenib, Ifosfamide; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Smoking Cessation
Interventions: NicVAX conjugate vaccine, Placebo; Biological
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Farmington, Connecticut + 6 more

Conditions: Prostate Cancer
Interventions: calcitriol, mitoxantrone hydrochloride, prednisone; Dietary Supplement · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Forehead Lines
Interventions: AGN-151586; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Newport Beach, California • New York, New York • Wilmington, North Carolina + 1 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 4 Years to 9 Years · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more

Conditions: Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Copanlisib, Radiologic Examination; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions: Support for Caregiver - Generic List, Support for Caregiver - Personalized List, Internet-Based Intervention - CONNECT, Patient Navigation; Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 25
States / cities: Denver, Colorado • Lafayette, Colorado • Lone Tree, Colorado + 21 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, pharmacological study, recombinant albumin fusion protein sEphB4-HSA; Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Cancer Survivor, Obesity, Overweight, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Aerobic Exercise, Exercise Counseling, Nutritional Assessment, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Non-small Cell Lung Cancer
Interventions: Pevonedistat, Docetaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Endometrial Cancer
Interventions: behavioral dietary intervention, exercise intervention, counseling intervention, educational intervention, survey administration; Behavioral · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Primary Myelofibrosis
Interventions: LY5830966; Drug
Lead sponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: Palo Alto, California • Tampa, Florida • Kansas City, Kansas + 8 more

Conditions: Metastatic Breast Cancer With Intracranial Metastases
Interventions: cabazitaxel, lapatinib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more

Conditions: Osteoarthritis of the Knee
Interventions: Diclofenac Sodium Active Topical Patch 1, Diclofenac Sodium Active Topical Patch 2, Placebo patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Jersey City, New Jersey

Search by objective public record fields.

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

A Study of LY3451838 in Participants With Migraine

Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

Efficacy of NicVAX in Smokers Who Want to Quit Smoking

Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer

A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis